Patent Assignment
Reel/Frame 066179/0074
Security Interest
Recorded: 2024-01-02
Pages: 152
Assignors
IMMUNITYBIO, INC.
Executed: 2023-12-29
NANTCELL, INC.
Executed: 2023-12-29
RECEPTOME, INC.
Executed: 2023-12-29
VBC HOLDINGS LLC
Executed: 2023-12-29
ALTOR BIOSCIENCE, LLC
Executed: 2023-12-29
ETUBICS CORPORATION
Executed: 2023-12-29
IGDRASOL, INC.
Executed: 2023-12-29
Assignee
INFINITY SA LLC, AS PURCHASER AGENT
C/O OBERLAND CAPITAL MANAGEMENT LLC, 1700 BROADWAY, 37TH FL, NEW YORK, NEW YORK, 10019
Covered Properties
(204)
Tumoricidal and Antimicrobial Compositions and Methods
Tumoricidal and Antimicrobial Compositions and Methods
NK-92 Cells to Stimulate Anti-Cancer Vaccine
Application:
16/760,893 →
Publication:
US 2021/0187024
Chimeric Antigen Receptor-Modified NK-92 Cells
Genetically Modified Nk-92 Cells Having a Safety Switch
Genetically Modified Nk-92 Cells with Decreased CD96/Tigit Expression
Application:
16/475,926 →
Publication:
US 2020/0123503
Hdac Inhibitors for Use with Nk Cell Based Therapies
Chemokine Responsive Activated Natural Killer Cells with Secondary Homing Activation for Verified Targets
Fc-Epsilon Car
Fc-Epsilon Car
Application:
18/179,995 →
Publication:
US 2023/0272042
Cryopreservation
Application:
17/260,545 →
Publication:
US 2021/0267190
Optimization of Nk-92 Cell Growth Using Poloxamer
Application:
17/057,494 →
Publication:
US 2021/0363484
Methods and Systems for Cell Bed Formation During Bioprocessing
Use of 5% Human Albumin in Wash and Harvest Media
Application:
16/964,962 →
Publication:
US 2021/0040451
Combined Invasion and Cytotoxicity Assay Using Chemokine Secreting Target Cells
Application:
17/264,601 →
Publication:
US 2021/0293787
Il-2 Dependent Nk-92 Cells with Stable Fc Receptor Expression
Application:
17/295,010 →
Publication:
US 2022/0017594
Generating Cik Nkt Cells from Cord Blood
Application:
17/260,544 →
Publication:
US 2022/0133789
Generating Cik Nkt Cells from Cord Blood
Elimination of Pd-L1-Positive Malignancies by Pd-L1 Chimeric Antigen Receptor-Expressing Nk Cells
Application:
17/356,411 →
Publication:
US 2021/0322477
Elimination of Pd-L1-Positive Malignancies by Pd-L1 Chimeric Antigen Receptor-Expressing Nk Cells
Application:
17/356,423 →
Publication:
US 2021/0315934
Sample Destruction Validation System and Methods
Application:
16/576,415 →
Publication:
US 2020/0096511
Quadricistronic System Comprising a Homing Receptor and Chimeric Antigen Receptor for Stable Genetic Modification of Cellular Immunotherapies
Elimination of CD19-Positive Lymphoid Malignancies by CD19-Car Expressing Nk Cells
Combination Therapies for Multiple Myeloma
Application:
17/292,701 →
Publication:
US 2022/0257649
RECOMBINANT erIL-15 NK CELLS
Mononuclear Cell Derived NK Cells
Antibody Pre-Loaded CD16+Nk-92 Cells as an Effective Therapeutic Product for Tumor Lysis
Application:
17/630,075 →
Publication:
US 2022/0265716
Anti-B7-H4 Chimeric Antigen Receptor-Modified NK-92 Cells
Primary NK CAR Constructs And Methods
Application:
17/311,226 →
Publication:
US 2022/0282216
Cell-mediated transient delivery of immune-enhancing molecules into the tumor microenvironment
Screening of cell clones expressing polygenic transgenes through non-antibiotic dependent positive selection
Application:
17/115,360 →
Publication:
US 2021/0169931
Elimination of BCMA-positive malignancies by CAR expressing NK cells
Application:
17/795,735 →
Publication:
US 2023/0172982
Chimeric Antigen Receptor-Modified Nk-92 Cells Targeting Egfr Super-Family Receptors
Method of Inducing Immunity Against Sars-Cov-2 Using Spike (S) and Nucleocapsid (N)-Etsd Immunogens Delivered by a Replication-Defective Adenovirus
Enzyme Based System for Production of Messenger RNA with Increased Transfection Efficiency
Application:
17/931,352 →
Publication:
US 2023/0183770
Neoepitope Vaccine Delivery Vehicle and Methods of Making the Same
Intratumorally Injected Yeast Vaccine
Nant COVID Vaccine Cross Reactivity
CIML NK cells and Methods Therefor
Application:
17/375,985 →
Publication:
US 2021/0361711
Content Authentication and Validation via Multi-Factor Digital Tokens, Systems, and Methods
Biological Deposit Labeling And Tracking Including Isotope, Rare Earth Metal Or Mitochondria Tags
CD16high CD57high NK-92MI Cells
Application:
18/195,588 →
Publication:
US 2023/0381313
Anti-Egfr/High Affinity Nk-Cells Compositions and Methods for Chordoma Treatment
Application:
17/727,560 →
Publication:
US 2022/0273722
Maximizing T-Cell Memory and Compositions and Methods Therefor
Application:
17/525,802 →
Publication:
US 2022/0072045
Nant Cancer Vaccine
Assessing Microsatellite Instability by Liquid Biopsy
Application:
17/270,407 →
Publication:
US 2021/0189505
Rapid Verification of Virus Particle Production for a Personalized Vaccine
Application:
18/067,508 →
Publication:
US 2023/0213518
Production And Delivery Tracking And Sample Verification Of Patient-Specific Therapeutics
Patent:
11,894,109 →
Application:
16/561,773 →
Neoepitope vaccine and immune stimulant combinations and methods
Application:
18/150,136 →
Publication:
US 2023/0145817
Treatment of Immunosuppressed Subjects
Methods of Treating Cancer
Object Storage And Access Management Systems And Methods
T Cells That Respond To Patient Neoepitopes
Application:
17/906,782 →
Publication:
US 2023/0236172
Electroporation With Active Compensation
Rapid Viral Diagnostic Test
Application:
17/401,079 →
Publication:
US 2022/0056542
Peptide Therapeutics Against SARS-COV-2 Spike Protein
Application:
17/929,805 →
Publication:
US 2023/0218743
Method of Inducing Immunity Against Sars-Cov-2 Using Spike and Nucleocapsid-Etsd Immunogens Delivered by Rna and Replication-Defective Adenoviruses
Methods for the Treatment of Covid-19 Comprising Adminstering Replication- Defective Adenoviruses Encoding the Sars-Cov-2 Spike Glycoprotein and Modified Nucleocapsid Protein
Drug-Specific Pharmacokinetic Assay for Il-15 Superagonist
Application:
18/006,668 →
Publication:
US 2023/0280356
Computerized Tool For Prediction of Proteasomal Cleavage
Application:
18/023,190 →
Publication:
US 2023/0326544
Rapid T-Cell Assay for Sars-Cov-2
Application:
17/544,586 →
Publication:
US 2022/0187279
HLA CLUSTERS, GLOBAL FREQUENCIES, AND BINDING ACROSS SARS-CoV-2 VARIATION
Systems and Methods of Analyzing Microbiomes Using Artificial Intelligence
Application:
18/196,227 →
Publication:
US 2023/0368377
Deep Learning Models For Tumor Evaluation
Waveform Analysis And Detection Using Machine Learning Transformer Models
Application:
17/376,955 →
Publication:
US 2022/0022798
Bacillus Calmette-Guerin (Bcg) and Antigen Presenting Cells for Treatment of Bladder Cancer
Vaccine Compositions for Mucosal Immune Response
Application:
18/246,279 →
Publication:
US 2023/0348935
Pharmaceutical Compositions to Enhance Phagocytosis Without Inflammation
Application:
17/613,602 →
Publication:
US 2022/0125866
Fusion Molecules Of CTLA4 And IL-15
HIV Treatment Compositions And Methods
Systems And Methods For Performing Segmentation Based On Tensor Inputs
haNK Cetuximab Combinations And Methods
Fusion Molecules and Il-15 Variants
Compositions Comprising Il-15-Based Molecules and Immune Checkpoint Inhibitor Antibodies
Method of Treating Cancer with Composition Comprising Il-15-Based Molecules and Bcg
Method for Treating Neoplasia with an Anti-CD38 Antibody and an Il-15:Il-15R Complex
Il-15-Based Molecules and Methods of Treating a Neoplasia
Il-15-Based Fusions to Il-12 and Il-18
Il-15-Based Fusions to Il-7 and Il-21
Human Immunodeficiency Virus-Specific T Cell Receptors
Nogapendekin Alfa-Inbakicept For Immune Stimulant Therapies And Treatment Of Viral Infections
Application:
17/594,940 →
Publication:
US 2022/0218789
Methods and Compositions for Producing an Adenovirus Vector for Use with Multiple Vaccinations
Application:
18/361,084 →
Publication:
US 2023/0364218
Automated and Dynamically Adjustable Gas Mixer for Bioreactor System
Application:
17/059,004 →
Publication:
US 2021/0230531
Segmentation-Based Image Processing For Confluency Estimation
Closed-System Method and Kit of Disposable Assemblies for Isolating Mesenchymal Stromal Cells from Lipoaspirate
Application:
17/496,269 →
Publication:
US 2022/0112467
Artificial Target Cells for in-vitro CAR Cytotoxicity and ADCC validation
Application:
16/985,090 →
Publication:
US 2021/0040175
Natural killer cell lines and methods of use
Tumoricidal and Antimicrobial Compositions and Methods
Tumoricidal and Antimicrobial Compositions and Methods
Tumoricidal and Antimicrobial Compositions and Methods
A Tumoricidal and Antimicrobial Composition
Tumoricidal and Antimicrobial Compositions and Methods
Tumoricidal and Antimicrobial Compositions and Methods
Modified Nk-92 Cells for Treating Cancer
Modified Nk-92 Cells for Treating Cancer
Chimeric Antigen Receptor-Modified NK-92 Cells
Genetically Modified Nk-92 Cells and Monoclonal Antibodies for the Treatment of Cancer
Genetically Modified Nk-92 Cells and Monoclonal Antiboides for the Treatment of Cancer
Genetically Modified Nk-92 Cells and Monoclonal Antiboides for the Treatment of Cancer
Genetically Modified Nk-92 Cells and Monoclonal Antibodies for the Treatment of Cancer
MODIFIED NK-92 haNK003 CELLS FOR THE CLINIC
MODIFIED NK-92 haNK003 CELLS FOR THE CLINIC
MODIFIED NK-92 haNK003 CELLS FOR THE CLINIC
Hiv Treatment Compositions and Methods
HIV Treatment Compositions And Methods
Fc-Epsilon Car
Use of CD33CAR Modified High Affinity Nk Cells (T-Hank) to Reduce Myeloid-Derived Suppressor Cells Suppressor Activity (or Reduce Negative Impact on Nk Cell Activity)
Generating Cik Nkt Cells from Cord Blood
Elimination of Pd-L1-Positive Malignancies by Pd-L1 Chimeric Antigen Receptor-Expressing Nk Cells
Quadricistronic System Comprising a Homing Receptor and Chimeric Antigen Receptor for Stable Genetic Modification of Cellular Immunotherapies
Quadricistronic System Comprising a Homing Receptor and Chimeric Antigen Receptor for Stable Genetic Modification of Cellular Immunotherapies
Quadricistronic System Comprising a Homing Receptor and Chimeric Antigen Receptor for Stable Genetic Modification of Cellular Immunotherapies
Elimination of CD19-Positive Lymphoid Malignancies by CD19-Car Expressing Nk Cells
RECOMBINANT erIL-15 NK CELLS
Mononuclear Cell Derived NK Cells
Chimeric Antigen Receptor-Modified Nk-92 Cells Targeting Egfr Super-Family Receptors
Content Authentication and Validation via Multi-Factor Digital Tokens, Systems, and Methods
Content Authentication and Validation via Multi-Factor Digital Tokens, Systems, and Methods
Content Authentication and Validation via Multi-Factor Digital Tokens, Systems, and Methods
Content Authentication and Validation via Multi-Factor Digital Tokens, Systems, and Methods
NK Cells with Altered CXCL12/CXCR4 Signaling
Methods of Immunogenic Modulation
Maximizing T-Cell Memory and Compositions and Methods Therefor
Sequence Arrangements and Sequences for Neoepitope Presentation
Hypoxic Nk Cells and Methods Therefor
Coordinated Multi-Prong Cancer Therapy
Nant Cancer Vaccine
Nant Cancer Vaccine
Targeted Neoepitope Vectors and Methods Therefor
Rapid Verification of Virus Particle Production for a Personalized Vaccine
Neoepitope vaccine and minnune stimulant combinations and methods
Tumor Treatment Method with an Individualized Peptide Vaccine
Treatment of Immunosuppressed Subjects
Object Storage And Access Management Systems And Methods
Replication-Defective Adenoviruses Comprising Nucleic Acids Encoding Sars-Cov-2 S Glycoprotein and Modified N Protein Comprising an Endosomal Targeting Sequence
IL-15 Agonist Drug Combinations For Immune Therapy
Patent:
11,318,189 →
Application:
17/313,285 →
Bacillus Calmette-Guerin (Bcg) and Antigen Presenting Cells for Treatment of Bladder Cancer
Bacillus Calmette-Guerin (Bcg) and Antigen Presenting Cells for Treatment of Bladder Cancer
Patent:
11,364,291 →
Application:
16/932,331 →
haNK CETUXIMAB COMBINATIONS AND METHODS
Superkine
Fusion Molecules and Il-15 Variants
Fusion Molecules and Il-15 Variants
Fusion Molecules and Il-15 Variants
Fusion Molecules and Il-15 Variants
Methods of Treating Disease with Fusion Molecules Comprising Il-15 Variants
Il-15 Variants and Uses Thereof
Interleukin 15 (Il-15) Variants
Fusion Molecules and Il-15 Variants
Patent:
11,498,950 →
Application:
16/659,311 →
Fusion Molecules and Il-15 Variants
Hiv Vpr-Specific T Cell Receptors
Hiv Vpr-Specific T-Cell Receptors
Hiv Vpr-Specific T-Cell Receptors
Multimeric Il-15 Soluble Fusion Molecules and Methods of Making and Using Same
Multimeric Il-15 Soluble Fusion Molecules and Methods of Treating Neoplasia and Hiv Using Same
Multimeric Il-15 Soluble Fusion Molecules and Methods of Making and Using Same
Multimeric Il-15 Soluble Fusion Molecules and Methods of Making and Using Same
Multimeric Il-15 Soluble Fusion Molecules and Methods of Making and Using Same
Multimeric Il-15 Soluble Fusion Molecules and Methods of Making and Using Same
Method of Treating Neoplasia with a Multimeric Il-15 Soluble Fusion Molecule
Multimeric Il-15 Soluble Fusion Molecules and Methods of Making and Using Same
Multimeric Il-15 Soluble Fusion Molecules and Methods of Making and Using Same
Multimeric Il-15 Soluble Fusion Molecules and Methods of Making and Using Same
Construction and Characterization of Multimeric Il-15-Based Molecules with CD3 Binding Domains
Il-15-Based Molecules and Methods of Use Thereof
Il-15-Based Molecules and Methods of Use Thereof
Il-15-Based Molecules and Methods of Use Thereof
Il-15-Based Molecules and Methods of Use Thereof
Il-15-Based Molecules and Methods of Use Thereof
Multimeric Il-15-Based Molecules
Multimeric Il-15-Based Molecules
Il-15-Based Fusions to Il-12 and Il-18
Il-15-Based Fusions to Il-12 and Il-18
Il-15-Based Fusions to Il-12 and Il-18
Il-15-Based Fusions to Il-7 and Il-21
Anti-PDL1, Il-15 and Tgf-Beta Receptor Combination Molecules
Methods of Inhibiting Viral Replication and Improving T Cell Function Employing Soluble Tim-3 Inhibitors.
Methods for Inhibiting Hiv or Hcv Infection by Administering Tim-3 Binding Inhibitors
Sequential Administration of a Replication Defective Adenovirus Vector in Vaccination Protocols
Sequential Administration of a Replication Defective Adenovirus Vector in Vaccination Protocols
Breast Cancer Vaccines and Methods of Use Thereof
Hpv Vaccines and Methods of Use Thereof
Methods and Compositions for Producing an Adenovirus Vector for Use with Multiple Vaccinations
Methods and Compositions for Producing an Adenovirus Vector for Use with Multiple Vaccinations
Methods and Compositions for Producing an Adenovirus Vector for Use with Multiple Vaccinations
Methods and Compositions for Producing an Adenovirus Vector for Use with Multiple Vaccinations
Replication Defective Adenovirus Vector in Vaccination
Replication Defective Adenovirus Vector in Vaccination
Human Adenovirus Serotype 5 Vectors Containing E1 and E2B Deletions Encoding the Ebolavirus Glycoprotein
Methods and Compositions for Combination Immunotherapy
Methods and Compositions for Combination Immunotherapy
Compositions and Methods for Flavivirus Vaccination
Compositions and Methods for Alphavirus Vaccination
Compositions and Methods for Tumor Vaccination and Immunotherapy Involving Her Antigens
Combination Immunotherapies Comprising Il-15 Superagonists
Combination Immunotherapies Comprising Il-15 Superagonists
Systems, Apparatus and Methods for Controlling a Movement of a Cell Culture to Optimize Cell Growth
Systems, Apparatus and Methods for Controlling a Movement of a Cell Culture to Optimize Cell Growth
Generation of Chimeric Antigen Receptor Mrna Molecules for Expression in Primary Nk Cells
PCT:
PCT/US2022/073727 ↗
Enzyme Based System for Production of Messenger Rna with Increased Transfection Efficiency
PCT:
PCT/US2022/076290 ↗
Neoepitope Vaccine Delivery Vehicle and Methods of Making the Same
PCT:
PCT/US2022/081025 ↗
Intratumorally Injected Yeast Vaccine
PCT:
PCT/US2023/063876 ↗
Natural Killer Cells for Chordoma Therapy
PCT:
PCT/US2022/048613 ↗
Nant Covid Vaccine Cross Reactivity
PCT:
PCT/US2022/080561 ↗
Modified T Cell Receptors for the Prevention and Treatment of Viral Infections and Cancer
PCT:
PCT/US2022/074202 ↗
Related Assignments
(25)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest
May 2, 2019
From: SOON-SHIONG, PATRICK
To: NANTKWEST, INC.
Reel/Frame 049067/0186 →
Assignment of Assignor's Interest
May 2, 2019
From: WOODY, JAMES N.
To: VIRACTA THERAPEUTICS, INC.
Reel/Frame 049078/0130 →
Assignment of Assignor's Interest
Jun 15, 2020
From: KLINGEMANN, HANS G.; BOISSEL, LAURENT H.; SCHOMER, NATHAN
To: NANTKWEST, INC.
Reel/Frame 052943/0655 →
Assignment of Assignor's Interest
Sep 29, 2020
From: BESSETTE, SHANNYN; ALI, SYED RAZA; SAXEN, MANJU
To: NANTKWEST, INC.
Reel/Frame 053921/0007 →
Assignment of Assignor's Interest
Dec 30, 2020
From: BESSETTE, SHANNYN; NGUYEN, DIEMCHI; ALI, SYED RAZA; SAXENA, MANJU
To: NANTKWEST, INC.
Reel/Frame 054775/0472 →
Assignment of Assignor's Interest
Jan 26, 2021
From: DUGGAL, ROHIT; SINHA, RANJEET
To: NANTKWEST, INC.
Reel/Frame 055040/0111 →
Assignment of Assignor's Interest
Jan 26, 2021
From: BESSETTE, SHANNYN; ALI, SYED RAZA; SAXENA, MANJU
To: NANTKWEST, INC.
Reel/Frame 055038/0931 →
Assignment of Assignor's Interest
May 12, 2021
From: BESSETTE, SHANNYN; NGUYEN, DIEMCHI
To: NANTKWEST, INC.
Reel/Frame 056222/0721 →
Assignment of Assignor's Interest
May 24, 2021
From: SCHOMER, NATHAN; BOISSEL, LAURENT; KLINGEMANN, HANS
To: NANTKWEST, INC.
Reel/Frame 056332/0686 →
Assignment of Assignor's Interest
Jun 22, 2021
From: SCHOMER, NATHAN THOMAS; BOISSEL, LAURENT H.; KLINGEMANN, HANS G.
To: NANTKWEST, INC.
Reel/Frame 056625/0577 →
Corrective Assignment to Correct the Priority 62539701 in the Assignment Document Previously Recorded at Reel: 056332 Frame: 0686. Assignor(S) Hereby Confirms the Assignment .
Jul 22, 2021
From: SCHOMER, NATHAN; BOISSEL, LAURENT; KLINGEMANN, HANS
To: NANTKWEST, INC.
Reel/Frame 056963/0658 →
Change of Name
Aug 2, 2021
From: NANTKWEST, INC.
To: IMMUNITYBIO, INC.
Reel/Frame 057059/0802 →
Assignment of Assignor's Interest
Aug 4, 2021
From: NANTWORKS, LLC
To: NANTKWEST
Reel/Frame 057079/0871 →
Assignment of Assignor's Interest
Aug 4, 2021
From: WITCHEY, NICHOLAS J.
To: NANTWORKS, LLC
Reel/Frame 057079/0778 →
Assignment of Assignor's Interest
Aug 4, 2021
From: BOISSEL, LAURENT H.; KLINGEMANN, HANS G.; DANDAPAT, ABHIJIT; CHINNAPEN, HIMANI
To: NANTKWEST, INC.
Reel/Frame 057079/0608 →
Assignment of Assignor's Interest
Aug 11, 2021
From: DANDAPAT, ABHIJIT; KLINGEMANN, HANS G.; BOISSEL, LAURENT H.
To: NANTKWEST, INC.
Reel/Frame 057145/0915 →
Assignment of Assignor's Interest
Aug 11, 2021
From: DANDAPAT, ABHIJIT; KLINGEMANN, HANS G.; BOISSEL, LAURENT H.
To: NANTKWEST, INC.
Reel/Frame 057148/0053 →
Change of Name
Aug 18, 2021
From: NANTKWEST, INC.
To: IMMUNITYBIO, INC.
Reel/Frame 057319/0192 →
Change of Name
Aug 18, 2021
From: NANTKWEST, INC.
To: IMMUNITYBIO, INC.
Reel/Frame 057220/0972 →
Change of Name
Aug 19, 2021
From: NANTKWEST, INC.
To: IMMUNITYBIO, INC.
Reel/Frame 057246/0697 →
Change of Name
Jul 28, 2022
From: NANTKWEST, INC.
To: IMMUNITYBIO, INC.
Reel/Frame 061003/0731 →
Assignment of Assignor's Interest
Jul 28, 2022
From: DUGGAL, ROHIT; SINHA, RANJEET
To: NANTKWEST, INC.
Reel/Frame 060663/0528 →
Assignment of Assignor's Interest
Oct 23, 2023
From: CAMPBELL, KERRY
To: INSTITUTE FOR CANCER RESEARCH D/B/A THE RESEARCH INSTITUTE OF FOX CHASE CANCER CENTER
Reel/Frame 065304/0975 →
Change of Name
Nov 9, 2023
From: NANTKWEST, INC.
To: IMMUNITYBIO, INC.
Reel/Frame 065534/0741 →
Change of Name
Mar 12, 2024
From: NANTKWEST, INC.
To: IMMUNITYBIO, INC.
Reel/Frame 066801/0776 →